Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women

@inproceedings{Konno2014EfficacyOT,
  title={Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women},
  author={Ryo Konno and Hiroyuki Yoshikawa and Marie Okutani and Wim G. V. Quint and Pemmaraju V Suryakiran and Lan Lin and Frank Struyf},
  booktitle={Human vaccines & immunotherapeutics},
  year={2014}
}
In this open, extended follow-up study (NCT00929526, Clinicaltrials.gov), we evaluated the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine efficacy, immunogenicity and safety up to 4 years after first vaccination in Japanese women aged 20-25 years. In the initial randomized, double-blind study (NCT00316693), 1040 women received the study vaccine or hepatitis A control vaccine; 752 women were included in the follow-up study. In women from the according-to-protocol efficacy cohort (ATP-E… CONTINUE READING